Heightened ability of monocytes from sarcoidosis patients to form multi-nucleated giant cells in vitro by supernatants of concanavalin A-stimulated mononuclear cells

被引:34
作者
Mizuno, K [1 ]
Okamoto, H [1 ]
Horio, T [1 ]
机构
[1] Kansai Med Univ, Dept Dermatol, Osaka 5708507, Japan
关键词
multi-nucleated giant cells; monocytes; purinergic receptors; sarcoidosis;
D O I
10.1046/j.1365-2249.2001.01655.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The main immunocompetent cells in sarcoidal lesions are epithelioid cells and multi-nucleated giant cells (MGC), both of which are derived from monocyte-macrophage lineage cells. To understand further the relevance of monocytes in sarcoidosis, we examined in vitro MGC formation using monocytes from sarcoidosis patients, patients with other granulomatous diseases (OGD) and healthy control subjects. The supernatant of concanavalin A-stimulated peripheral blood mononuclear cells (conditioned medium) generated Langhans type-MGC and foreign body type-MGC from monocytes. Conditioned medium from any three groups had the same ability to form MGC from normal monocytes. On the other hand, MGC were more highly formed using monocytes from sarcoidosis patients than from other groups. When macrophages induced by treatment of monocytes with macrophage colony-stimulating factor (M-CSF) were used, the rate of MGC formation in sarcoidosis patients was about threefold or fourfold as much as that in OGD patients or healthy controls, respectively. Oxidized ATP inhibited MGC formation in all groups. The susceptibility of monocytes cultured in conditioned medium for 24 h to 2'- and 3'-o-(4-benzoyl-benzoyl)ATP-mediated cytolysis was significantly higher in sarcoidosis patients than other groups. These findings suggest that the ability of monocytes to form MGC through P2x(7) receptors is enhanced in sarcoidosis patients.
引用
收藏
页码:151 / 156
页数:6
相关论文
共 24 条
[1]  
Agostini C, 1998, J IMMUNOL, V161, P6413
[2]  
BECKER S, 1987, J IMMUNOL, V139, P3703
[3]  
Bergeron A, 1997, J IMMUNOL, V159, P3034
[4]   Pharmacological characterization of recombinant human and rat P2X receptor subtypes [J].
Bianchi, BR ;
Lynch, KJ ;
Touma, E ;
Niforatos, W ;
Burgard, EC ;
Alexander, KM ;
Park, HS ;
Yu, HX ;
Metzger, R ;
Kowaluk, E ;
Jarvis, MF ;
van Biesen, T .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 376 (1-2) :127-138
[5]   Blockade of human P2X7 receptor function with a monoclonal antibody [J].
Buell, G ;
Chessell, IP ;
Michel, AD ;
Colo, G ;
Salazzo, M ;
Herren, S ;
Gretener, D ;
Grahames, C ;
Kaur, R ;
Kosco-Vilbois, MH ;
Humphrey, PPA .
BLOOD, 1998, 92 (10) :3521-3528
[6]   Interleukin 16 and its function as a CD4 ligand [J].
Center, DM ;
Kornfeld, H ;
Cruikshank, WW .
IMMUNOLOGY TODAY, 1996, 17 (10) :476-481
[7]   Pharmacological characterization of the human P2Y11 receptor [J].
Communi, D ;
Robaye, B ;
Boeynaems, JM .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 128 (06) :1199-1206
[8]   PRODUCTION OF THE RANTES CHEMOKINE IN DELAYED-TYPE HYPERSENSITIVITY REACTIONS - INVOLVEMENT OF MACROPHAGES AND ENDOTHELIAL-CELLS [J].
DEVERGNE, O ;
MARFAINGKOKA, A ;
SCHALL, TT ;
LEGERRAVET, MB ;
SADICK, M ;
PEUCHMAUR, M ;
CREVON, MC ;
KIM, T ;
GALANAUD, P ;
EMILIE, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (05) :1689-1694
[9]   ATP receptors and giant cell formation [J].
Di Virgilio, F ;
Falzoni, S ;
Chiozzi, P ;
Sanz, JM ;
Ferrari, D ;
Buell, CN .
JOURNAL OF LEUKOCYTE BIOLOGY, 1999, 66 (05) :723-726
[10]   EXTRACELLULAR ATP AS A POSSIBLE MEDIATOR OF CELL-MEDIATED CYTOTOXICITY [J].
DIVIRGILIO, F ;
PIZZO, P ;
ZANOVELLO, P ;
BRONTE, V ;
COLLAVO, D .
IMMUNOLOGY TODAY, 1990, 11 (08) :274-277